Definition:
The market Other Pharmaceuticals covers revenues for areas that are not specifically mentioned in the other markets, such as psychotropic or gastroenterology drugs and less expensive but widely used drugs, such as cold and cough remedies or analgesics.
Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).
Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.
Most recent update: Jun 2024
Source: Statista Market Insights
Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.
Most recent update: Mar 2024
The Other Pharmaceuticals market in Saudi Arabia is experiencing significant growth due to a combination of customer preferences, local special circumstances, and underlying macroeconomic factors.
Customer preferences: Saudi Arabia has a growing population and an increasing demand for healthcare services, which is driving the growth of the Other Pharmaceuticals market. Customers in Saudi Arabia prefer to purchase high-quality pharmaceutical products that are effective and affordable. They also prefer to purchase products from trusted brands and suppliers. As a result, pharmaceutical companies are investing in research and development to create new and innovative products that meet the needs of customers in Saudi Arabia.
Trends in the market: The Other Pharmaceuticals market in Saudi Arabia is experiencing several trends that are driving growth. One trend is the increasing prevalence of chronic diseases such as diabetes, cardiovascular disease, and cancer. This is driving demand for pharmaceutical products that can help manage these conditions. Another trend is the increasing use of digital technologies to improve healthcare services. This is creating opportunities for pharmaceutical companies to develop new products that integrate digital technologies, such as mobile health apps and wearable devices.
Local special circumstances: Saudi Arabia has a unique set of circumstances that are driving growth in the Other Pharmaceuticals market. The government has made significant investments in healthcare infrastructure and services, which is creating opportunities for pharmaceutical companies to expand their operations in the country. Additionally, the government has implemented policies to encourage foreign investment in the healthcare sector, which is attracting international pharmaceutical companies to the country.
Underlying macroeconomic factors: Several underlying macroeconomic factors are driving growth in the Other Pharmaceuticals market in Saudi Arabia. These include a growing population, increasing urbanization, and rising incomes. As the population grows and becomes more urbanized, demand for healthcare services and pharmaceutical products is expected to increase. Rising incomes are also driving demand for high-quality healthcare services and pharmaceutical products.Overall, the Other Pharmaceuticals market in Saudi Arabia is experiencing significant growth due to a combination of customer preferences, local special circumstances, and underlying macroeconomic factors. As the market continues to grow, pharmaceutical companies will need to continue investing in research and development to create new and innovative products that meet the needs of customers in Saudi Arabia.
Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.
Most recent update: Sep 2024
Source: Statista Market Insights
Most recent update: Jun 2024
Source: Statista Market Insights
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Notes: Based on data from IMF, World Bank, UN and Eurostat
Most recent update: Sep 2024
Source: Statista Market Insights